全文获取类型
收费全文 | 36204篇 |
免费 | 2206篇 |
国内免费 | 110篇 |
专业分类
耳鼻咽喉 | 321篇 |
儿科学 | 1166篇 |
妇产科学 | 1011篇 |
基础医学 | 4944篇 |
口腔科学 | 616篇 |
临床医学 | 5926篇 |
内科学 | 6575篇 |
皮肤病学 | 598篇 |
神经病学 | 3444篇 |
特种医学 | 606篇 |
外科学 | 3123篇 |
综合类 | 403篇 |
一般理论 | 55篇 |
预防医学 | 4528篇 |
眼科学 | 468篇 |
药学 | 2119篇 |
中国医学 | 68篇 |
肿瘤学 | 2549篇 |
出版年
2023年 | 197篇 |
2022年 | 383篇 |
2021年 | 775篇 |
2020年 | 459篇 |
2019年 | 779篇 |
2018年 | 896篇 |
2017年 | 619篇 |
2016年 | 647篇 |
2015年 | 833篇 |
2014年 | 1171篇 |
2013年 | 1779篇 |
2012年 | 2652篇 |
2011年 | 2802篇 |
2010年 | 1528篇 |
2009年 | 1286篇 |
2008年 | 2540篇 |
2007年 | 2545篇 |
2006年 | 2564篇 |
2005年 | 2385篇 |
2004年 | 2305篇 |
2003年 | 2183篇 |
2002年 | 2041篇 |
2001年 | 220篇 |
2000年 | 151篇 |
1999年 | 298篇 |
1998年 | 412篇 |
1997年 | 367篇 |
1996年 | 326篇 |
1995年 | 279篇 |
1994年 | 271篇 |
1993年 | 253篇 |
1992年 | 166篇 |
1991年 | 138篇 |
1990年 | 134篇 |
1989年 | 128篇 |
1988年 | 106篇 |
1987年 | 113篇 |
1986年 | 90篇 |
1985年 | 107篇 |
1984年 | 155篇 |
1983年 | 157篇 |
1982年 | 194篇 |
1981年 | 167篇 |
1980年 | 159篇 |
1979年 | 93篇 |
1978年 | 74篇 |
1977年 | 81篇 |
1976年 | 60篇 |
1975年 | 53篇 |
1974年 | 68篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Emeline Colomba Patricia Pautier Fanny Pommeret Alexandra Leary 《Expert review of anticancer therapy》2019,19(6):437-446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
2.
3.
Daniel D. Billadeau Subrha Chatterjee Patricia Bramati Raghavakaimal Sreekumar Vijay Shah Karen Hedin Raul Urrutia 《Journal of gastrointestinal cancer》2006,37(4):110-119
CXCL12 and its receptor, CXCR4, are emerging as promising targets for modulating growth, angiogenesis, and metastasis in several human cancers. Indeed, blocking the receptor is sufficient to prevent metastasis and angiogenesis in experimental breast cancer xenografts. Recently, the biological effect of the CXCR4 in pancreatic cancer, one of the most deadly neoplastic diseases, has been reported. However, the molecular mechanism by which CXCR4 contributes to these properties is not completely understood. In this paper, we characterize the signaling pathways activated by CXCR4 in pancreatic cancer. We show that after CXCR4 activation, EGFR becomes tyrosine phosphorylated, and the kinase activity of this receptor, together with the activation of MMPs, Src, and PI3-Kinase, is required for CXCR4-mediated ERK activation. Analysis of this cascade in pancreatic cancer cells revealed that the ERK-mediated pathway regulates genes involved in angiogenesis, such as VEGF, CD44, HIF1α, and IL-8. Furthermore, ERK blockage inhibits the migration and tube formation of endothelial cells induced by CXCL12. Considering that inhibitors for several components of this pathway, including CXCR4 itself, are at different stages of clinical trials, this study provides theoretical justification for the clinical testing of these drugs in pancreatic cancer, thus extending the list of potential targets for treating this dismal disease. 相似文献
4.
5.
6.
Cheryl Wallerstedt RNC MS Patricia Higgins RN PhD 《Journal of obstetric, gynecologic, and neonatal nursing : JOGNN / NAACOG》1996,25(5):389-400
Society often expects mothers and fathers to share equally in the perinatal grief process because the child was a common bond between them. Unfortunately, in perinatal grief, this is not always the case. The mother and the father can experience incongruent grieving and use discordant coping mechanisms. It is important to evaluate these differences to facilitate communication between the distraught parents. Improved communication can in turn facilitate the grieving process. 相似文献
7.
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Bayard L. Powell Hyman B. Muss Robert L. Capizzi Mary E. Caponera Douglas R. White Patricia J. Zekan James N. Atkins Don V. Jackson Jr. Frederick Richards II John B. Craig Julia M. Cruz Charles L. Spurr 《Cancer chemotherapy and pharmacology》1987,19(3):250-252
Summary Cytosine arabinsodie (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9–12 and 21–24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2×2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.Supported in part by grants from the National Cancer Institute (CA-12197 and CA-09422) and the American Cancer Society CF-85-182 相似文献
8.
Joseph M Dhahbi Shelley X Cao Patricia L Mote Brian C Rowley John E Wingo Stephen R Spindler 《The Journal of nutrition》2002,132(1):31-37
Molecular chaperones assist in the biosynthesis and processing of proteins. Most chaperones are induced by physiological stresses. We have shown that dietary energy restriction decreases the mRNA and protein levels of many endoplasmic reticulum chaperones in the livers of mice. Here, we have investigated the response of chaperone mRNA to feeding. Control and 50% energy-restricted C3B10RF1 mice were deprived of food for 24 h, fed, and killed 0, 1.5, 5 or 12 h after feeding. Chaperone mRNAs were strongly induced as early as 1.5 h after feeding in control and energy-restricted mice. The integrated levels of these mRNA over 24 h were significantly lower in energy-restricted mice. The mRNA response to energy intake was mirrored over the course of days in the level of chaperone protein. A similar but smaller response to feeding was found in kidney and muscle. Puromycin and cycloheximide failed to inhibit the feeding response, suggesting that feeding releases chaperone expression from an unstable inhibitor. Studies with dibutyryl-cAMP- and glucagon-supplemented, normal and streptozotocin-diabetic mice suggest that glucagon and insulin may be mediators of the feeding response. Adrenalectomy enhanced the feeding induction, but dexamethasone administration had no effect. Thus, postprandial changes in insulin and glucagon may link chaperone gene expression to feeding, possibly in several tissues including liver. 相似文献
9.
10.
The use of N-acetylcysteine has increased in the prevention of radiographic contrast induced nephrotoxicity. Many nurses need to be aware of the proper administration and action of this prophylactic agent. This article discusses the research behind the use of N-acetylcysteine and the protocol for administration to prevent radiographic contrast-induced nephrotoxicity. 相似文献